CymaBay Therapeutics, Inc.
Simbols: CBAY
NASDAQ
32.48
USDTirgus cena šodien
-32.9591
P/E koeficients
0.0000
PEG koeficients
3.73B
MRK Cap
- 0.00%
DIV ienesīgums
CymaBay Therapeutics, Inc. (CBAY) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1283.24 | 394.3 | 135.5 | 186.5 | ||||||||||||
balance-sheet.row.short-term-investments | 708.35 | 187.7 | 115.2 | 60.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-current-assets | 35.01 | 9.5 | 2.6 | 4.6 | ||||||||||||
balance-sheet.row.total-current-assets | 1318.25 | 403.8 | 138.1 | 191.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 7.83 | 5.7 | 0.9 | 1.4 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-investments | 22.36 | 22.4 | 0 | 8.1 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.other-non-current-assets | 9.26 | 2.8 | 2.9 | 1.7 | ||||||||||||
balance-sheet.row.total-non-current-assets | 39.45 | 30.9 | 3.8 | 11.2 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.account-payables | 12.78 | 3.8 | 1.1 | 2.7 | ||||||||||||
balance-sheet.row.short-term-debt | 11.12 | 10 | 0.7 | 0.6 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.long-term-debt-total | 397.14 | 99.2 | 90.3 | 51 | ||||||||||||
Deferred Revenue Non Current | 3.3 | 1.1 | 0 | 0 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -203.34 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 58.31 | 21.3 | 13.7 | 15.1 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 405.76 | 105.6 | 90.3 | 51 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 6.43 | 5.3 | 0.7 | 1.3 | ||||||||||||
balance-sheet.row.total-liab | 526.66 | 142.4 | 105.7 | 69.4 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0.06 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.retained-earnings | -3718.63 | -978.2 | -872.9 | -766.9 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.11 | 0.1 | -0.3 | 0 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 4549.72 | 1270.3 | 909.3 | 899.8 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1357.7 | 434.7 | 141.9 | 202.3 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 831.04 | 292.3 | 36.2 | 132.9 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1357.7 | - | - | - | ||||||||||||
Total Investments | 730.71 | 210.1 | 115.2 | 68.8 | ||||||||||||
balance-sheet.row.total-debt | 413.58 | 114.5 | 90.9 | 51.6 | ||||||||||||
balance-sheet.row.net-debt | -161.31 | -92 | 70.6 | -74.2 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -105.37 | -105.4 | -106 | -90 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
cash-flows.row.deferred-income-tax | -7.77 | -2.7 | 0 | 0.6 | ||||||||||||
cash-flows.row.stock-based-compensation | 15.23 | 15.2 | 9.5 | 10 | ||||||||||||
cash-flows.row.change-in-working-capital | 5.63 | 5.6 | -2.3 | 6.4 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.account-payables | 2.73 | 2.7 | -1.4 | 2.3 | ||||||||||||
cash-flows.row.other-working-capital | 2.9 | 2.9 | -0.9 | 4 | ||||||||||||
cash-flows.row.other-non-cash-items | 19.06 | 14 | 14 | 2.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -72.53 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.acquisitions-net | -2.11 | -7.9 | -0.9 | 0.6 | ||||||||||||
cash-flows.row.purchases-of-investments | -305.67 | -305.7 | -175 | -78.1 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 219.55 | 219.6 | 129.1 | 126.8 | ||||||||||||
cash-flows.row.other-investing-activites | 2.11 | 7.9 | 0.9 | -0.6 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -86.57 | -86.6 | -46 | 48.6 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -25 | -47.7 | ||||||||||||
cash-flows.row.common-stock-issued | 339.36 | 345.8 | -0.5 | 70.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -0.5 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -25 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 7.46 | 335.1 | 75.5 | 95.7 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 345.77 | 345.8 | 24.6 | 118.5 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 26.59 | -0.4 | 0 | 0 | ||||||||||||
cash-flows.row.net-change-in-cash | 186.24 | 186.2 | -105.5 | 97.6 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 574.89 | 206.5 | 20.3 | 125.8 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 388.64 | 20.3 | 125.8 | 28.2 | ||||||||||||
cash-flows.row.operating-cash-flow | -72.53 | -72.5 | -84.1 | -69.4 | ||||||||||||
cash-flows.row.capital-expenditure | -0.45 | -0.4 | -0.1 | -0.1 | ||||||||||||
cash-flows.row.free-cash-flow | -72.98 | -73 | -84.2 | -69.5 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 31.07 | 31.1 | 0 | 0 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0.68 | 0.7 | 0.7 | 0.7 | ||||||||||||
income-statement-row.row.gross-profit | 30.39 | 30.4 | -0.7 | -0.7 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 80.74 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 51.95 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 132.7 | 132.1 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.cost-and-expenses | 132.75 | 132.8 | 93.1 | 87.6 | ||||||||||||
income-statement-row.row.interest-income | 13.49 | 13.5 | 2 | 0.2 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 1.76 | 1.8 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | -1.7 | -3.7 | -12.9 | -2.4 | ||||||||||||
income-statement-row.row.interest-expense | 9.26 | 18.9 | 14.9 | 2.6 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 3.18 | 0.7 | 2 | 0.9 | ||||||||||||
income-statement-row.row.ebitda-caps | -94.8 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | -101.68 | -101.7 | -93.1 | -87.6 | ||||||||||||
income-statement-row.row.income-before-tax | -105.37 | -105.4 | -106 | -90 | ||||||||||||
income-statement-row.row.income-tax-expense | 11.99 | 0 | 12.9 | 2.6 | ||||||||||||
income-statement-row.row.net-income | -111.68 | -105.4 | -118.9 | -92.6 |
Biežāk uzdotie jautājumi
Kas ir CymaBay Therapeutics, Inc. (CBAY) kopējie aktīvi?
CymaBay Therapeutics, Inc. (CBAY) kopējie aktīvi ir 434686000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 57000.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.978.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.644.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -3.594.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -3.272.
Kāda ir CymaBay Therapeutics, Inc. (CBAY) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -105370000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 114494000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 132071000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 206535000.000.